Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT ID: NCT02273375
Last Updated: 2025-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1415 participants
INTERVENTIONAL
2015-02-24
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT02125461
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
NCT02763579
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
NCT02087423
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
NCT02087176
Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3
NCT00273507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEDI4736
MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
MEDI4736
Placebo
PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEDI4736
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be classified post-operatively as Stage IB (≥ 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
* Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques
Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status.
Prior Systemic Therapy:
* Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible.
* Patients may have received prior post-operative platinum based chemotherapy as per standard of care.
* No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible.
Radiation:
• Patients with N2 disease only who receive adjuvant post-operative radiation therapy are eligible provided they meet the protocol specified timing criteria for surgery, adjuvant chemotherapy and randomization. Pre-operative radiation therapy is not permissible.
* The patient must have an ECOG performance status of 0, 1.
* Hematology: . Absolute neutrophil count ≥ 1.5 x 109/L or ≥ 1,500/µl Platelets ≥ 100 x 109/L or ≥ 100,000/µl
* Biochemistry:
Total bilirubin\* ≤ institutional upper limit of normal Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ≤ 2.5 x institutional upper limit of normal Creatinine Clearance ≥ 40 ml/min
\* excluding Gilbert's syndrome
Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula:
Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L
* Patient able and willing to complete the QoL, economics and other questionnaires. The baseline assessment must already have been completed within required timelines prior to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
* Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
* Protocol treatment is to begin within 2 working days of patient randomization
Exclusion Criteria
* adequately treated non-melanoma skin cancer,
* curatively treated in-situ cancer, or
* other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
* A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC).
* History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded.
* History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization\* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.
* Live attenuated vaccination administered within 30 days prior to randomization.
* History of hypersensitivity to MEDI4736 or any excipient.
* Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, must have a LVEF \> 50% within 12 weeks prior to randomization.
* Concurrent treatment with other investigational drugs or anti-cancer therapy.
* Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:
* known clinical diagnosis of tuberculosis;
* known active hepatitis B infection (positive HBV surface antigen (HBsAg)). Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible;
* known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA;
* known human immunodeficiency virus infection (positive HIV antibodies).
* known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function
* Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Thoracic Oncology Group of Australasia (TOGA)
UNKNOWN
National Health and Medical Research Council, Australia
OTHER
National Cancer Institute (NCI), Naples
UNKNOWN
Central and Eastern European Oncology Group
OTHER
Dutch Society of Physicians for Pulmonology and Tuberculosis
OTHER
Korean Cancer Study Group
OTHER
Fundación GECP
OTHER
West Japan Oncology Group (WJOG)
UNKNOWN
Chinese Thoracic Oncology Group
UNKNOWN
Canadian Cancer Trials Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenwood Goss
Role: STUDY_CHAIR
Ottawa Hospital Research Institute, Ontario, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
USC Norris/Comprehensive Cancer Centre
Los Angeles, California, United States
National Jewish Health
Denver, Colorado, United States
University of Florida
Gainesville, Florida, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Duke University Medical Center
Durham, North Carolina, United States
Hematology and Oncology Associates of NEPA
Dunmore, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
The Reading Hospital Medical Center
West Reading, Pennsylvania, United States
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Coffs Habour Health Campus - NCCI
Coffs Harbour, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St. George Hospital, Cancer Care Centre
Kogarah, New South Wales, Australia
Liverpool Cancer Therapy Centre, Liverpool Hospital
Liverpool, New South Wales, Australia
Northern Cancer Institute St Leonards
St Leonards, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Mater Medical Centre
Brisbane, South, QLD, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Frankston Hospital - Peninsula Oncology Centre
Frankston, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Royal Melbourne Hospital Research Foundation
Parkville, Victoria, Australia
Epworth HealthCare - Richmond
Richmond, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
St John of God Subiaco
Subiaco, Western Australia, Australia
Flinders Medical Center
Adelaide, , Australia
Canberra Hospital
Garran, , Australia
St. Vincent's Hospital
Victoria Park, , Australia
Suporte Nutricional e Quimioterapia LTDA PRONUTRIR
Fortaleza, Ceará, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Espírito Santo, Brazil
Cetus Hospital Dia Oncologia
Belo Horizonte, Minas Gerais, Brazil
Liga Norte Riograndense Contra o Cancer
Natal, Rio Grande do Norte, Brazil
Instituto Tacchini de Pesquisa em Saude
Bento Gonçalves, Rio Grande do Sul, Brazil
Centro de Oncologia e Radioterapia (COR) Mae de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, Brazil
Faculdade de Medicina do ABC
São Paulo, Santo Andre, Brazil
Fundacao Faculdade Regional de Medicina
São José do Rio Preto, São Paulo, Brazil
Instituto Nacional de Cancer (INCA)
Rio de Janeiro, , Brazil
MHAT Serdika - Medical Oncology Clinic
Sofia, , Bulgaria
MHAT Nadezhda Hospital
Sofia, , Bulgaria
Medical Centre Synexus
Sofia, , Bulgaria
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
BCCA - Abbotsford Centre
Abbotsford, British Columbia, Canada
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
The Moncton Hospital
Moncton, New Brunswick, Canada
Regional Health Authority B, Zone 2
Saint John, New Brunswick, Canada
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Health Sciences North
Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Algoma District Cancer Program
Sault Ste. Marie, Ontario, Canada
Niagara Health System
St. Catharines, Ontario, Canada
Thunder Bay Regional Health Sciences Centre/Thunder
Thunder Bay, Ontario, Canada
Humber River Hospital
Toronto, Ontario, Canada
Odette Cancer Centre
Toronto, Ontario, Canada
Sinai Health System
Toronto, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
PEI Cancer Treatment Centre
Charlottetown, Prince Edward Island, Canada
Lévis, Quebec, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
The Jewish General Hospital
Montreal, Quebec, Canada
The Research Institute of the McGill University
Montreal, Quebec, Canada
Centre Integre Universitaire De Sante Et De Services
Montreal, Quebec, Canada
University Institute of Cardiology and
Québec, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Province Cancer Hospital
Fuzhou, Fujian, China
Guangdong General Hospital
Guangzhou, Guangdong, China
The Second Affiliated Hosp of Shantou Medical Colleg
Shantou, Guangdong, China
The People Hospital of Guangxi Zhuang Autonomous Reg
Nanning, Guangxi, China
Henan province Cancer Hospital
Zhengzhou, Henan, China
The Second Xiangya Hospital of Central South Univer
Changsha, Hunan, China
The First People Hospital of Yueyang
Yueyang, Hunan, China
Nanjing General Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital Of Xuzhou Medical College
Xuzhou, Jiangsu, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Northern Jiangsu People Hospital
Yangzhou, Jiangsu, China
Shandong Cancer Hospital
Jinan, Shandong, China
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Yunnan Provincial Cancer Hospital
Kunming, Yunnan, China
Sir run run shaw hospital School of Medicine
Hangzhou, Zhejiang, China
CRLCC - Paoli-Calmette
Marseille, BP, France
Hopital de la Croix-Rousse
Lyon, Cedex 04, France
Centre hospitalier universitaire de Montpellier
Montpellier, Cedex 05, France
AP-HP Hopital Tenon
Paris, Cedex 20, France
Hopital Albert Michallon
Grenoble, Cedex 9, France
CHRU de Tours - Hopital Bretonneau
Tours, Tours Cedex 9, France
CHU - Angers
Angers, , France
Centre Hospitalier - Avignon
Avignon, , France
Institut Sainte Catherine
Avignon, , France
Bayonne - Centre Hospitalier
Bayonne, , France
Hopital Jean Minjoz
Besançon, , France
Hopital Avicenne
Bobigny, , France
Polyclinique Bordeaux Nord
Bordeaux, , France
Boulogne - Ambroise Pare
Boulogne, , France
Caen - CHU
Caen, , France
Centre Hospitalier de Chambery
Chambéry, , France
Centre Hospitalier de Cholet
Cholet, , France
HIA Percy
Clamart, , France
Clermont-Ferrand - CHU
Clermont-Ferrand, , France
Hopital Louis Pasteur
Colmar, , France
Annemasse - Centre Hospitalier Alpes Leman
Contamine-sur-Arve, , France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, , France
Centre Hospitalier Intercommunal de Creteil
Créteil, , France
CHU Hopital du Bocage
Dijon, , France
Centre Hospitalier Intercommunal - Elbeuf
Elbeuf, , France
Centre Hospitalier departemental
La Roche-sur-Yon, , France
Versailles - CH Andre Mignot
Le Chesnay, , France
Centre Hospitalier du Mans
Le Mans, , France
Lille - Hopital Calmette
Lille, , France
Centre Hospitalier Lyon Sud
Lyon, , France
Hopital Europeen
Marseille, , France
Marseille - Hopital Nord
Marseille, , France
Centre Hospitalier les Chanaux
Mâcon, , France
CH de la Region d'Annecy
Metz-Tessy, , France
Centre Hospitalier de Mulhouse
Mulhouse, , France
Centre Antoine Lacassagne - Nice
Nice, , France
Centre Hospitalier Regional Hopital de la Source
Orléans, , France
Hopital Saint Louis
Paris, , France
Fondation Hopital Saint Joseph
Paris, , France
Paris - HEGP
Paris, , France
Paris - Institut Curie
Paris, , France
Hopital Bichat
Paris, , France
Centre Hospitalier General de Pau
Pau, , France
Centre Hospitalier de Perigueux
Périgueux, , France
Centre Hospitalier Rene Dubos
Pontoise, , France
CHU de Rouen
Rouen, , France
Institut de Cancerologie de la Loire
Saint-Priest-en-Jarez, , France
Centre Hospitalier de Saint-Quentin
Saint-Quentin, , France
Nouvel Hopital Civil Hopitaux
Strasbourg, , France
Suresnes - Foch
Suresnes, , France
Thonon-les-Bains - Hopital Georges Pianta
Thonon-les-Bains, , France
CHITS Toulon Sainte Musse
Toulon, , France
Hopital Larrey
Toulouse, , France
Villefranche sur Saone - CH
Villefranche-sur-Saône, , France
Semmelweis University Pulmonology Department
Budapest, , Hungary
AOU Ospedali Riuniti Umberto I
Torrette, AN, Italy
Azienda Ospedaliera San Giuseppe Moscati
Avellino, AV, Italy
IRCCS Ospedale Oncologico Giovanni Paolo II
Bari, BA, Italy
Instituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
Ospedale S. Paolo - U.O. di Oncologia Medica
Milan, MI, Italy
Azienda Ospedaliera di Perugia Santa Maria
Perugia, PG, Italy
Centro di Riferimento Oncologico - CRO
Aviano, PN, Italy
Fondazione Salvatore Maugeri Oncologia Medica
Pavia, PV, Italy
OUC Oncologia Medica - Presidio Ospedaliero
Ravenna, RA, Italy
Oncologia Medica IRCCS Arcispedale Maria
Reggio Emilia, RE, Italy
Istituti Fisioterapici Ospitalieri IFO Istituto
Rome, RM, Italy
A.O. Busto Arsizio - P.O. Saronno
Saronno, VA, Italy
AOU Integrata Verona Policlinico GB
Verona, VR, Italy
U.O. di Oncologia Medica Azienda Ospedaliera G Rummo
Benevento, , Italy
PO A Perrino ASL Brindisi - UOC Oncologia Medica
Brindisi, , Italy
AOU Policlinico Vittorio Emanuele UOC di Oncologia
Catania, , Italy
U.O. di Oncologia Ospedale Villa Scassi
Genova, , Italy
Intstituto Scientifico Romangnolo
Meldola, , Italy
European Institute of Oncology
Milan, , Italy
U.O.C. di Oncologia U.L.S.S. 13
Mirano, , Italy
Azienda Ospedaliera di Rilievo Nazionale
Napoli, , Italy
Dott. Fortunato Ciardiello,Cattedra Oncologia Medica
Napoli, , Italy
Unita Sperimentazioni Cliniche Istituto per lo
Napoli, , Italy
Universita Federico II UOC Oncologia Medica
Napoli, , Italy
UOC Oncologia Medica II Instituto Oncologio Veneto
Padua, , Italy
Azienda USL di Piacenza, Ospedale Gugliemimo Salieto
Piacenza, , Italy
Azienda Ospedaliera S. Camillo-Forlanin
Rome, , Italy
Japanese Red Cross Nagoya Daiichi Hospital
Nagoya, Aichi-ken, Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
Hospital of the University of Occupational and
Kitakyushu, Fukuoka, Japan
Gifu Univiesity Hospital
Gifu, Gifu, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
National Hospital Organization Kure Medical Center
Kure, Hiroshima, Japan
Koube University Hospital
Kobe, Hyōgo, Japan
Hyogo College of Medicine
Nishinomiya-shi, Hyōgo, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
Sendai Kousei Hospital
Sendai, Miyagi, Japan
Kurashiki Central Hospital
Kurashiki, Okayama-ken, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Kinki University Hospital Faculty of Medicine
Ōsaka-sayama, Osaka, Japan
National Hospital Organization Kinki-Chuo
Sakai, Osaka, Japan
Tottori University Hospital
Yonago, Tottori, Japan
National Hospital Organization Yamaguchi
Ube, Yamaguchi, Japan
Chiba University Hospital
Chiba, , Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Osaka City General Hospital
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Juntendo University Hospital
Tokyo, , Japan
Tokyo Medical University Hospital
Tokyo, , Japan
Kanagawa Cancer Center
Yokohama, , Japan
Universitair medisch centrum Nijmegen st Radboud
Nijmegen, Gelderland, Netherlands
Amphia ziekenhuis
Breda, North Brabant, Netherlands
Tergooi locatie Hilversum
Hilversum, North Holland, Netherlands
Isala
Zwolle, Overijssel, Netherlands
Netherlands Cancer Institute
Amsterdam, , Netherlands
Free University Hospital
Amsterdam, , Netherlands
UMC Groningen
Groningen, , Netherlands
Academical Hospital Maastricht
Maastricht, , Netherlands
Erasmus Medical Center (EMC)
Rotterdam, , Netherlands
Christchurch Hospital
Christchurch, , New Zealand
Klinika Onkologii i Radioterapii Uniwersyteckie
Gdansk, , Poland
Specjalistyczny Szpital im
Szczecin, , Poland
Samodzielny Publiczny Szpital Specjalistyczny
Zakopane, , Poland
Conformal Med Terra HIFU
Bucharest, , Romania
Spitalul de Psihiatrie Dr. Constantin Gorgos
Bucharest, , Romania
Oncology Institute Bucharest
Bucharest, , Romania
Oncological Institute "Ion Chiricuta"
Cluj-Napoca, , Romania
OCH - Ovidius Clinical Hospital
Constanța, , Romania
Centrul de Oncologie Sf Nectarie
Craiova, , Romania
SC Oncolab SRL
Craiova, , Romania
Spital Lotus SRL
Ploieşti, , Romania
National University Hospital
Singapore, , Singapore
Keimyung University Dongsan Medical Center
Daegu, Dalseogu, South Korea
Chung Ang University Hospital
Seoul, Dongjak Gu, South Korea
Veterans Health Service Medical Center
Seoul, Gangdong-gu, South Korea
The Catholic University of Korea Bucheon
Bucheon-si, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Uijeongbu ST Marys Hospital
Gyeonggi-do, , South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
The Catholic University of Korea,
Seoul, , South Korea
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Mutua de Terrassa
Terrassa, Barcelona, Spain
Hospital Insular de Gran Canaria
Las Palmas, Gran Canaria, Spain
Hospital Teresa Herrera
A Coruña, , Spain
Hospital General de Alicante
Alicante, , Spain
Hoapital Quiron Dexeus
Barcelona, , Spain
Hospital Vall d Hebron
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Duran i Reynals
Barcelona, , Spain
Complejo Asistencial Universitario de Leon
León, , Spain
Hospital Universitario la Princesa
Madrid, , Spain
Hospital Puerta de Hierro
Madrid, , Spain
Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Son Llatzer
Palma de Mallorca, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Far Eastern Memorial Hospital
New Taipei City;, Taiwan, Taiwan
Chang-Gung Memorial Hospital - Chiayi
Chiayi City, , Taiwan
Kaohsiung Medical University
Kaohsiung City, , Taiwan
E-Da Hospital
Kaohsiung City, , Taiwan
Chang-Gung Memorial Hospital - Kaohsiung
Kaohsiung City, , Taiwan
Taipei Medical University - Shuang Ho Hospital
New Taipei City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Mackay Memorial Hospital
Taipei, , Taiwan
Veterans General Hospital - Taipei
Taipei, , Taiwan
Tri-Service General Hospital
Taipei, , Taiwan
Chang-Gung Memorial Hospital - Linkou
Taoyuan District, , Taiwan
Dnipropetrovsk City Clinical Hospital No.4
Dnipropetrovsk, , Ukraine
Regional Oncology Center
Sumy, , Ukraine
Vinnytsia Regional Clinical Oncology Dispensary
Vinnitsia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT1401
Identifier Type: OTHER
Identifier Source: secondary_id
ACTRN12615000323527
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1238-5923
Identifier Type: OTHER
Identifier Source: secondary_id
BR31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.